XERS
Xeris Biopharma Holdings, Inc. Common Stock
Nasdaq · usd
Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades at $10.26 (+0.61%) as of 2:22:02 PM EDT on Oct 26, 2026, +12.79% over the past month. Market cap is $1.86B, with 1.7 days to cover in short interest.
Stock performance
How Xeris Biopharma Holdings, Inc. Common Stock (XERS) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.63%
- 1W
- -6.26%
- 1M
- +12.79%
- YTD
- +30.75%
- 1Y
- +10.25%
- 52-wk range
- $5.25 – $11.42
Key statistics
Today's trading snapshot for XERS: day range, open, previous close, volume and market cap.
- Day range
- $10.18 – $10.41
- Open
- $10.22
- Prev close
- $10.20
- Volume
- 935.75K
- Market cap
- $1.86B
- Shares out
- 182.32M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Xeris Biopharma Holdings, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 5.54
- P/B
- -191.05
- P/FCF
- 33.41
- ROE
- 176.3%
- ROA
- -4.2%
- Debt/Equity
- -25.95
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Xeris Biopharma Holdings, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Patent milestoneOct 14, 2026
These lawsuits were filed following the grant of U.S. Patent No. 12,758,502 (the "'502 patent") related to the Company's KEVEYIS® (dichlorphenamide) product.
- Investor presentationSep 9, 2026
The Company will host an XP-8121 Program Overview (Webinar) on September 9, 2026. A copy of the slide presentation to be used by the Company's senior management in discussions with investors (the "Presentation") is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
- Quarterly earningsAug 6, 2026
On August 6, 2026, Xeris Biopharma Holdings, Inc. (the "Company") issued a press release containing information about the Company's results of operations and business highlights for the three and six months ended June 30, 2026.
- Warrant or conversionJul 17, 2026
On July 15, 2026, a holder of $10.5 million in principal amount of the 2028 Notes elected to convert their 2028 Notes into approximately 3.6 million shares of the Company's common stock (the 'Conversion').
- Equity compensation grantJun 30, 2026
In connection with her appointment, Dr. Kreher was granted an initial equity award consisting of options to purchase shares of the Company's common stock and restricted stock units having a combined aggregate grant date fair value of approximately $450,000 under the Company's non-employee director compensation program.
XERS short interest
How heavily XERS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 1.7
- Short interest
- 7.2M
- Avg volume
- 4.15M
As of · reported to FINRA twice monthly.
XERS news
The latest news and headlines about Xeris Biopharma Holdings, Inc. Common Stock (XERS).
- Xeris (XERS) Q2 Revenue Jumps 49%positiveThe Motley Fool· Aug 7, 2025
- Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research· May 9, 2024
- Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?Zacks Investment Research· Apr 17, 2024
- Xeris Biopharma: Checking-In On One Of My 'Top Ideas'Seeking Alpha· Mar 30, 2024
- Why Xeris (XERS) Might Surprise This Earnings SeasonZacks Investment Research· Mar 5, 2024
Frequently asked questions
What is the Xeris Biopharma Holdings, Inc. Common Stock (XERS) stock price today?
Xeris Biopharma Holdings, Inc. Common Stock (XERS) is trading at $10.26 (+0.61% on the day) as of 2:22:02 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Xeris Biopharma Holdings, Inc. Common Stock?
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States.
What is the short interest in XERS?
As of Sep 30, 2026, XERS has 7.2M shares short and 1.7 days to cover.
What exchange is XERS listed on?
Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of XERS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a XERS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.